Volume 91, special issue 2, Numéro spécial, Mai 2004

Editorial

Inhibiteurs de la cyclo‐oxygénase 2 et cancer (p.59-60)
Thierry André, Jean‐Charles Soria

Synthèse

Cyclooxygenase 2 and carcinogenesis (p.61-76)
Sylvie Rodrigues, Erik Bruyneel, Christelle M. Rodrigue, Emami Shahin, Christian Gespach

Cyclooxygenase 2 inhibitors and cancer chemoprevention (p.77-84)
Amine Masmoudi, Thierry Le Chevalier, Laure Sabatier, Jean‐Charles Soria

Cyclooxygenase 2 inhibitors and adenomatous polyposis coli (p.85-8)
Christian Florent, Nathalie Meary

Cyclooxygenase 2 inhibitors and colorectal cancer (p.89-98)
Marianne Bernardeau‐Mozer, Stanislas Chaussade

Cyclooxygenase 2 and breast cancer (p.99-108)
Jean‐Paul Guastalla, Thomas Bachelot, Isabelle Ray‐Coquard

Cyclooxygenase 2 inhibitors and lung carcinoma (p.109-12)
Jean‐Philippe Spano, Kader Chouahnia, Jean‐François Morère

Cyclooxygenase 2 inhibitors and urologic and gynaecologic cancers (p.113-6)
Pascal Eschwege

Safety of the selective inhibitors the inducible cyclooxygenase‐2 taken for long period (p.117-24)
Dominique Lamarque

Analgesic effects of cyclooxygenase 2 inhibitors (p.125-31)
Christian Jayr